Clinical trials: PD-L1 Gene Amplification
PD-L1 Gene Mutation, PD-L1 Gene Amplification
Programmed Cell Death Ligand 1 PET/CT in Various PD-L1-Related Disease Patients
To evaluate the potential usefulness of 68Ga/18F-PD-L1 positron emission tomography/computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in various PD-L1-related disease patients
- Conditions
- PD-L1 Gene Mutation, PD-L1 Gene Amplification, PD-L1-related Disease, Positron Emission Tomography
- Trial name
- NCT07618936
- Testing
- Single Group Assignment
- Where
- 3 sites in China
- Volunteers
- 500 people
- Sponsor
- Tianjin Medical University
NSCLC Stage IV, PD-L1 Gene Amplification
PD-L1 PET Imaging in Patients With the Immunotherapy for Non-small Cell Lung Cancer
Clinical trials have shown efficacy of PD1/PD-L1 checkpoint inhibitors in multiple solid tumors, including NSCLC. Whole body information with regard to target presence, drug kinetics and dynamics, as well as binding of PD-L1…
- Trial name
- NCT05533086
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Xiaohua Zhu
Metastatic Gastric Cancer, PD-L1 Gene Amplification
Nivolumab in Combination With Chemotherapy for FGFR2-positive Metastatic Gastric Cancer
The goal of this phase 2 clinical trial is to evaluate the efficacy of nivolumab in combination with CAPOX in patients with FGFR2-positive/PD-L1-positive/HER2-negative metastatic gastric cancer.
- Conditions
- Metastatic Gastric Cancer, PD-L1 Gene Amplification, FGFR2 Amplification
- Trial name
- NIVOFGFR2 (NCT05859477)
- Testing
- Nivolumab, Capecitabine, Oxaliplatin
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Kidney Cancer Research Bureau